FBLG FibroBiologics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1958777 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY11.3%
TTM EPS YoY169.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,696.9%
ROA-211.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets73.2%
Debt / equity0.00x
Current ratio1.22x
Interest coverage-71.97x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-36.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.08M | $1.66M | $2.95M | $797,000 | $2.79M | $2.04M | $1.78M | $1.36M |
| SG&A expense | $2.00M | $2.38M | $2.12M | $1.79M | $2.25M | $2.45M | $2.75M | $2.36M |
| Operating income | -$4.07M | -$4.03M | -$5.07M | -$2.59M | -$5.04M | -$4.49M | -$4.53M | -$3.71M |
| Interest expense | $4,000 | $7,000 | $4,000 | $204,000 | $0 | $0 | $0 | $6,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$4.05M | -$4.12M | -$5.00M | -$3.24M | -$5.78M | -$4.66M | -$4.97M | -$3.10M |
| EBITDA | -$4.00M | -$3.97M | -$5.00M | -$2.52M | -$4.97M | -$4.43M | -$4.48M | -$3.67M |
| EPS (basic) | -0.38 | -0.66 | -1.33 | — | -2.68 | -2.41 | -2.71 | — |
| EPS (diluted) | -0.38 | -0.66 | -1.33 | — | -2.68 | -2.41 | -2.71 | — |
| Weighted avg. shares (diluted) | 10.59M | 6.27M | 3.77M | — | 2.15M | 1.93M | 1.83M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.17M | $3.52M | $1.48M | $4.89M | $4.87M | $8.85M | $8.67M | $13.98M |
| Current assets | $4.78M | $5.85M | $2.90M | $6.35M | $5.24M | $10.18M | $9.33M | $14.23M |
| PP&E, net | $661,000 | $710,000 | $776,000 | $842,000 | $908,000 | $967,000 | $814,000 | $824,000 |
| Total assets | $6.75M | $7.93M | $5.94M | $9.62M | $8.74M | $13.91M | $11.43M | $16.45M |
| Current liabilities | $3.93M | $2.21M | $1.83M | $1.76M | $6.72M | $10.96M | $8.21M | $12.73M |
| Total liabilities | $4.94M | $3.29M | $3.34M | $3.46M | $8.62M | $13.05M | $9.08M | $13.71M |
| Shareholders' equity | $1.81M | $4.64M | $2.60M | $6.16M | $125,000 | $860,000 | $2.35M | $2.73M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.75M | -$3.29M | -$4.36M | -$3.16M | -$3.97M | -$3.98M | -$5.28M | -$3.07M |
| Capital expenditure | $18,000 | $0 | $0 | $0 | $6,000 | $213,000 | $43,000 | $99,000 |
| Free cash flow | -$2.77M | -$3.29M | -$4.36M | -$3.16M | -$3.98M | -$4.20M | -$5.32M | -$3.17M |
| Investing cash flow | -$18,000 | $0 | $0 | $0 | -$6,000 | -$213,000 | -$43,000 | -$99,000 |
| Financing cash flow | $426,000 | $5.32M | $952,000 | $3.19M | $0 | $4.38M | $0 | $9.33M |
| Depreciation & amortization | $66,000 | $66,000 | $66,000 | $66,000 | $65,000 | $60,000 | $53,000 | $47,000 |
| Stock-based compensation | $671,000 | $707,000 | $694,000 | $702,000 | $704,000 | $729,000 | $551,000 | $544,000 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.